Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease

Translational Research

Volumn 152, Issue 2, 2008, Pages 88-94

  Rice, Kathryn L ^a   Leimer, Inge ^a   Kesten, Steven ^a   Niewoehner, Dennis E ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; PLACEBO; TIOTROPIUM BROMIDE;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART DISEASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SPIROMETRY;

EID: 50949132697     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.05.011     Document Type: Article

References (31)

1. Halbert R.J., Isonaka S., George D., and Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease?. Chest 123 (2003) 1684-1692
2. Mannino D.M., Homa D.M., Akinbami L.J., Moorman J.E., Gwynn C., and Redd S.C. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 51 (2002) 1-16
3. Jemal A., Ward E., Hao Y., and Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 294 (2005) 1255-1259
4. Wise R.A. Changing smoking patterns and mortality from chronic obstructive pulmonary disease. Prev Med 26 (1997) 418-421
5. Chatila W.M., Wynkoop W.A., Vance G., and Criner G.J. Smoking patterns in African Americans and whites with advanced COPD. Chest 125 (2004) 15-21
6. Dransfield M.T., Davis J.J., Gerald L.B., and Bailey W.C. Ethnic and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Respir Med 100 (2005) 1110-1116
7. Vollmer W.M., Enright P.L., Pedula K.L., et al. Ethnicity and gender differences in the effects of smoking on lung function. Chest 117 (2000) 764-772
8. Egede L.E., and Zheng D. Ethnic/ethnic differences in influenza vaccination coverage in high-risk adults. Am J Public Health 93 (2003) 2074-2078
9. Silverman B.G., Gross T.P., and Babish J.D. Home oxygen therapy care beneficiaries, 1991-1992. Chest 112 (1997) 380-386
10. Taylor A.L., Ziesche S., Yancy C., et al., African-american heart failure trial investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
11. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M., and SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
12. Niewoehner D.E., Rice K., Cote C., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a long-acting inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med 143 (2005) 317-326
13. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277 (1997) 925-926
14. Chodosh S., Flanders J.S., Kesten S., Serby C.W., Hochrainer D., and Witek Jr. T.J. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 14 (2001) 309-315
15. Standardization of spirometry - 1994 update: statement of the American Thoracic Society. Am J Respir Crit Care Med 152 (1995) S77-S120
16. Morris J.F., Koski A., Temple W.P., Claremont A., and Thomas D.R. Fifteen year interval spirometric evaluation of the Oregon predictive equations. Chest 93 (1988) 123-127
17. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2005) 948-968
18. Criner G.J., Sharafkhaneh A., Conoscenti C.S., Johnson P., Keyser M.T., and Cassino C. Efficacy of tiotropium powder in African-American patients with chronic obstructive pulmonary disease. J COPD 5 (2008) 35-41
19. Burchard E.G., Ziv E., Coyle N., et al. The importance of ethnicity and ethnic background in biomedical research and clinical practice. N Engl J Med 348 (2003) 1170-1175
20. Dransfield M.T., and Bailey W.C. COPD: ethnic disparities in susceptibility, treatment, and outcomes. Clin Chest Med 27 (2006) 463-471
21. Jha A.K., Shlipak M.G., Hosmer W., Frances C.D., and Browner W.S. Ethnic differences in mortality among men hospitalized in the Veterans Affairs health care system. JAMA 285 (2001) 297-303
22. Gordon H.S., Johnson M.L., and Ashton C.M. Process of care in hispanic, black, and white VA beneficiaries. Med Care 40 (2002) 824-833
23. Wilt T.J., Niewoehner D.E., MacDonald R., and Kane R.L. Diagnosis and management of stable chronic obstructive pulmonary disease. Ann Intern Med 147 (2007) 639-653
24. Sehgal A.R. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 43 (2004) 566-572
25. Bibbins-Domingo K., and Fernandez A. BiDil for heart failure in black patients: Implications of the U.S. Food and Drug Administration approval. Ann Intern Med 146 (2007) 52-56
26. Temple R., and Stockbridge N.L. BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective. Ann Intern Med 146 (2007) 57-62
27. Relling M.V., Lin J.S., Ayers G.D., and Evans W.E. Ethnic and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52 (1992) 643-658
28. Tornatore K.M., Reed K.A., and Venuto R.C. Ethnic differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Pharmacotherapy 13 (1993) 481-486
29. Benowitz N.L., Perez-Stable E.J., Fong I., Modin G., Herrera B., and Jacob III P. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291 (1999) 1196-1203
30. Bjornsson T.D., Wagner J.A., Donahue S.R., et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 43 (2003) 943-967
31. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 97 (2000) 10483-10488